(Sharecast News) - Shares in Angle tanked on Wednesday after the cancer treatment tech group delivered a cautious outlook, pointing to only "modest" growth compared with the 31% surge in revenues seen in 2024.
The company, whose technology harvests circulating tumour cell (CTC) from the blood for analysis, reported strong annual...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE